You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MDS who have received <6 cycles of treatment with hypomethylating agents (HMAs)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MDS Trial in Worldwide (MBG453, Placebo, Hypomethylating agents)

Active, not recruiting
  • Myelodysplastic Syndromes
  • Duarte, California
  • +46 more
Jan 20, 2023

MDS Trial run by the National Cancer Institute (NCI) (KPT-8602, Inqovi)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 30, 2023

MDS (MDS) Trial in United Kingdom (Sodium Valproate, Bezafibrate, Medroxyprogesterone, Danazol)

Recruiting
  • Myelodysplastic Syndromes (MDS)
  • Sodium Valproate, Bezafibrate, Medroxyprogesterone
  • Danazol
  • Dudley, England, United Kingdom
  • +7 more
Aug 12, 2022

MDS (MDS) Trial in United States (Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine)

Completed
  • Myelodysplastic Syndromes (MDS)
  • Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine
  • Chicago, Illinois
  • +11 more
Apr 4, 2022

Myelodysplastic Syndrome (MDS) Trial in United States (MBG453, Azacitidine, Decitabine)

Recruiting
  • Myelodysplastic Syndrome (MDS)
  • Chandler, Arizona
  • +22 more
Dec 5, 2022

Low Risk MDS Trial (R906289 Monosodium (R289 Na))

Not yet recruiting
  • Low Risk Myelodysplastic Syndromes
  • R906289 Monosodium (R289 Na)
  • (no location specified)
Jul 22, 2022

Acute Myeloid Leukemia, MDS Trial (Cladribine, Cytarabine, Decitabine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • (no location specified)
Mar 1, 2023

MDS, Acute Myeloid Leukemia Trial in Australia, France, Germany (Imetelstat)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Acute Myeloid Leukemia
  • Adelaide, Australia
  • +11 more
Oct 13, 2022

MDS, Leukemia, Myelomonocytic, Chronic Trial in Worldwide (Guadecitabine, Treatment Choice)

Completed
  • Myelodysplastic Syndromes
  • Leukemia, Myelomonocytic, Chronic
  • Duarte, California
  • +95 more
Sep 1, 2021

Hypomethylating Agent, Venetoclax, Myeloid Malignancy Trial in Shanghai (Venetoclax, Azacitidine or decitabine)

Recruiting
  • Hypomethylating Agent
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai Jiao Tong University School of Medicine Affilated Shang
May 2, 2023

Acute Myeloid Leukemia Trial in Worldwide (MBG453, Venetoclax, Azacitidine)

Active, not recruiting
  • Acute Myeloid Leukemia
  • Birmingham, Alabama
  • +27 more
Jan 20, 2023

MDS Trial in New Haven (CPX-351)

Withdrawn
  • MDS
  • New Haven, Connecticut
    Yale University; Smilow Cancer Center
Jan 6, 2022

MDS Trial in United States (Pracinostat, Azacitidine)

Terminated
Has Results
  • Myelodysplastic Syndromes
  • Duarte, California
  • +24 more
Feb 4, 2022

MDS/MPN Trial in Nanjing (Azacitidine (AZA) with Ruxolitinib)

Recruiting
  • MDS/MPN
  • Azacitidine (AZA) with Ruxolitinib
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital of Nanjing Medical University
Apr 17, 2023

MDS, Secondary Acute Myeloid Leukemia Trial in Tampa (CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes,

Recruiting
  • Myelodysplastic Syndromes
  • Secondary Acute Myeloid Leukemia
  • CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes
  • Standard of Care Chemotherapy
  • Tampa, Florida
    Moffitt Cancer Center
Sep 27, 2022

MDS, Myeloproliferative Tumor, Anemia Trial in Tampa (Luspatercept)

Recruiting
  • Myelodysplastic Syndromes
  • +2 more
  • Tampa, Florida
    Moffitt Cancer Center
Feb 16, 2023

Recurrent IDH1/2 Mutated Glioma Trial in Paris (Azacitidine)

Recruiting
  • Recurrent IDH1/2 Mutated Glioma
  • Paris, France
    Pitie Salpetriere Hospital
Aug 29, 2022

Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome, Low-risk Myelodysplastic Syndrome Trial in France, Germany,

Completed
  • Acute Myeloid Leukemia
  • +2 more
  • Nantes, Nantes Cedex 1, France
  • +7 more
Dec 20, 2021

Registry on Hypomethylating Agents in Myeloid Neoplasms

Active, not recruiting
  • Chronic Myelomonocytic Leukemia
  • +2 more
  • non interventional
  • Feldkirch, Austria
  • +19 more
Jul 20, 2021

MDS Trial in Beijing (Lenalidomide, Azacitidine)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Beijing, China
    Peking union medical college hospital
Aug 16, 2023

Acute Myeloid Leukemia, MDS, Glioblastoma Multiforme Trial in United States (DSP-7888 Dosing Emulsion)

Completed
  • Acute Myeloid Leukemia
  • +8 more
  • DSP-7888 Dosing Emulsion
  • Denver, Colorado
  • +7 more
Apr 4, 2022

MDS Trial run by the National Cancer Institute (NCI) (decitabine and cedazuridine, BMS-986253)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome Trial in Philadelphia

Recruiting
  • Myelodysplastic Syndrome
  • +2 more
  • Navitoclax
  • +6 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Feb 2, 2023

MDS Trial (Imetelstat)

Available
  • Myelodysplastic Syndromes
  • (no location specified)
Jun 30, 2023

Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome Trial in Houston (Fostamatinib)

Recruiting
  • Refractory Chronic Myelomonocytic Leukemia
  • Refractory Myelodysplastic Syndrome
  • Houston, Texas
    M D Anderson Cancer Center
Aug 31, 2021